Arch Biopartners (TSXV:ARCH) - Stock Price, News & Analysis

ARCH Stock Overview

Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada.

About the company

ARCH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 4.3% per year over the past 5 years

Risk Analysis

Negative shareholders equity

Has less than 1 year of cash runway

Does not have meaningful revenue (CA$2M)

Arch Biopartners Inc. Competitors

Sona Nanotech

CNSX:SONA

CA$41.6m

Innovotech

TSXV:IOT

CA$5.1m

NervGen Pharma

TSXV:NGEN

CA$148.9m

HLS Therapeutics

TSX:HLS

CA$151.5m

Price History & Performance

Summary of all time highs, changes and price drops for Arch Biopartners
Historical stock prices
Current Share Price	US$2.31
52 Week High	US$2.56
52 Week Low	US$0.97
Beta	1.34
1 Month Change	-5.71%
3 Month Change	50.98%
1 Year Change	10.00%
3 Year Change	84.80%
5 Year Change	75.00%
Change since IPO	507.89%

Recent updates

Shareholder Returns

	ARCH	CA Life Sciences	CA Market
7D	-1.7%	-4.1%	-0.6%
1Y	10.0%	-6.7%	3.9%

Return vs Industry: ARCH exceeded the Canadian Life Sciences industry which returned -6.7% over the past year.

Return vs Market: ARCH exceeded the Canadian Market which returned 3.9% over the past year.

Price Volatility

Is ARCH's price volatile compared to industry and market?
ARCH volatility
ARCH Average Weekly Movement	7.8%
Life Sciences Industry Average Movement	7.0%
Market Average Movement	9.1%
10% most volatile stocks in CA Market	18.3%
10% least volatile stocks in CA Market	3.1%

Stable Share Price: ARCH's share price has been volatile over the past 3 months.

Volatility Over Time: ARCH's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Richard Muruve	www.archbiopartners.com

Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals.

Arch Biopartners Inc. Fundamentals Summary

How do Arch Biopartners's earnings and revenue compare to its market cap?
ARCH fundamental statistics
Market cap	CA$145.99m
Earnings (TTM)	-CA$1.95m
Revenue (TTM)	CA$1.85m

79.0x

P/S Ratio

-74.8x

P/E Ratio

Is ARCH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARCH income statement (TTM)
Revenue	CA$1.85m
Cost of Revenue	CA$1.81m
Gross Profit	CA$32.20k
Other Expenses	CA$1.98m
Earnings	-CA$1.95m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.031
Gross Margin	1.74%
Net Profit Margin	-105.69%
Debt/Equity Ratio	-88.2%

How did ARCH perform over the long term?

See historical performance and comparison

ARCH Stock Overview

Rewards

Risk Analysis

Arch Biopartners Inc. Competitors

CNSX:SONA

CA$41.6m

TSXV:IOT

CA$5.1m

TSXV:NGEN

CA$148.9m

TSX:HLS

CA$151.5m

Price History & Performance

Recent News & Updates

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Recent updates

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.035 loss in 1Q 2023)

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.008 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.003 loss in 1Q 2022)

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Insufficient new directors

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Third quarter 2021 earnings released: EPS CA$0.014 (vs CA$0.037 loss in 3Q 2020)

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

New 90-day low: CA$1.25

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

New 90-day low: CA$1.26

Full year 2020 earnings released: CA$0.077 loss per share (vs CA$0.036 loss in FY 2019)

New 90-day low: CA$1.37

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

New 90-day high: CA$1.56

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

New 90-day low - CA$1.24

Third quarter earnings released

New 90-day low - CA$1.25